Filing summary
Entity and period: The supplied metadata identifies TERAWULF INC., but the filing text is IKONICS CORPORATION’s unaudited Form 10-Q for the quarter ended September 30, 2019. The summary below reflects the filing text; confirm the company and filing match before relying on it.
Business context and reporting period
IKONICS reports four business segments: Chromaline, IKONICS Imaging, Digital Texturing (DTX), and Advanced Material Solutions (AMS). The filing compares the three and nine months ended September 30, 2019 with the same periods in 2018. Foreign sales were approximately 29% of sales for the first nine months in both years.
Financial performance
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Net sales | $4.53 million | $4.65 million | $12.66 million | $13.36 million |
| Gross profit / margin | $1.41 million / 31.2% | $1.53 million / 32.8% | $3.85 million / 30.4% | $4.55 million / 34.1% |
| Operating income (loss) | $(154,000) | $(22,000) | $(886,000) | $34,000 |
| Net income (loss) | $(163,000) | $(25,000) | $(733,000) | $(10,000) |
| Loss per share, diluted | $(0.08) | $(0.01) | $(0.37) | $(0.01) |
For the first nine months, operating cash flow was negative $620,000, versus positive $1.07 million in 2018. Investing activities used $90,000 and financing activities used $154,000. Cash and equivalents declined to $759,000 from $1.62 million at year-end 2018; short-term investments were $2.45 million. Cash, equivalents, and short-term investments totaled approximately $3.21 million.
At September 30, total debt was approximately $2.85 million, including $132,000 current and $2.72 million long-term. The company had no borrowings on its $2.05 million line of credit, renewed through August 30, 2021. Current assets were $8.95 million and current liabilities $2.11 million. Total stockholders’ equity was $12.33 million.
Material changes and drivers
- Q3 sales fell 2.6%; nine-month sales fell 5.3%. Chromaline sales were pressured by weaker domestic demand, Chinese tariffs, and first-quarter cold-weather shipping constraints. AMS sales declined year to date due to lower sales to two large customers. DTX comparisons were affected by an approximately biennial film order in 2018.
- IKONICS Imaging grew 14.5% in Q3, helped by film and equipment sales and the new IKONART product; its nine-month sales were essentially flat.
- Gross margin contracted in both comparison periods. Management cited Chromaline’s lower volume, less favorable mix, tariffs, and higher raw-material costs, plus lower-margin DTX sales mix. AMS margins improved with lower costs.
- Year-to-date R&D expense rose to $668,000 from $490,000, primarily due to additional staffing. The company also wrote off $87,000 of previously capitalized patent application costs after discontinuing those applications.
- Operating cash use reflected the net loss and working-capital movements, including a $527,000 inventory increase and a $577,000 increase in prepaid expenses and other assets. The latter included a $694,000 medical-insurance reimbursement receivable; accrued health-insurance costs also increased.
Outlook, risks, and unusual items
- Management expects approximately $240,000 of additional 2019 capital expenditures for coating capability, process improvements, and information technology, funded with existing cash and operating cash flow.
- Management plans to continue product development and R&D, pursue DTX initiatives and AMS opportunities, and grow international sales. It noted the strong U.S. dollar makes international growth more challenging. No quantified revenue or earnings guidance is provided.
- The company was not in compliance with its rolling debt-service-coverage covenant at September 30, 2019, but obtained a waiver. Management warned that future violations without waivers could materially adversely affect liquidity. The loan and credit line are secured by substantially all company assets.
- The company recorded a $34,000 incremental valuation allowance against deferred tax assets, citing cumulative losses as negative evidence. The filing reports no unrecognized tax benefits, no current tax examinations, no legal proceedings, and no off-balance-sheet arrangements.
- The company repurchased 7,199 shares for approximately $50,000 in the first nine months. The filing reports effective disclosure controls and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Confirm the filing’s registrant: the supplied metadata says TERAWULF INC., while the document identifies IKONICS CORPORATION.
- Review the debt covenant waiver terms, the covenant calculation, and the company’s ability to comply in future periods.
- Assess whether operating cash flow can recover, particularly given the net loss, increased inventory, and timing and collectability of the insurance reimbursement receivable.
- Track sales and margin trends by segment, especially Chromaline’s exposure to tariffs, raw-material costs, and domestic demand, and the progress of IKONART, DTX, and AMS initiatives.
- Evaluate the realizability of deferred tax assets and the expected cash needs for planned capital expenditures.